• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Oral semaglutide effectively reduces bodyweight in non-diabetic adults with obesity

byNeel MistryandTeddy Guo
September 15, 2023
in Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in the placebo group.

2. Any-grade adverse events were more common among the semaglutide group with the most common being mild-to-moderate severity gastrointestinal symptoms.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with overweight or obese body-mass-indices (BMIs) often struggle with weight management on conservative therapy. In such patients, glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide, may be helpful in lowering body weight while also reducing blood glucose. Although the role of semaglutide in patients with type 2 diabetes is well-established, its use among adults without type 2 diabetes mellitus remains unclear. This randomized controlled trial aimed to assess the safety and efficacy of semaglutide versus placebo for treating overweight or obesity in non-diabetic adults. The primary outcome of this study was percentage change in body weight from baseline to 68 weeks, while the key secondary outcome was the proportion of patients achieving a body weight reduction ≥ 5%. According to study results, oral semaglutide led to a significant reduction in body weight compared to placebo. Although this study was well done, it was limited by a high occurrence of medication-related adverse events.

Click to read the study in The Lancet

Relevant Reading: Once-Weekly Semaglutide in Adults with Overweight or Obesity

RELATED REPORTS

Red meat consumption may be associated with an increased risk of type 2 diabetes

Wellness Check: Nutrition

#VisualAbstract: Dapagliflozin does not reduce albuminuria in patients with heart failure and type 2 diabetes (DAPPER study)

In-depth [randomized-controlled trial]: Between Sept 13 and Nov 22, 2021, 709 patients were screened for eligibility across 50 outpatient clinics in 9 countries. Included were patients with a BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with complications, and no type 2 diabetes. Altogether, 667 patients (334 in semaglutide 50 mg and 333 in placebo) were included in the final analysis. The primary outcome of mean change in body weight was significantly greater in the semaglutide 50 mg group (-15.1%, standard error [SE] 0.5) versus placebo (-2.4%, SE 0.5, p<0.0001). This was also the case for the proportion of patients who reached bodyweight reduction ≥ 5% (85% semaglutide 50 mg vs. 26% placebo, odds ratio [OR] 12.6, 95% confidence interval [CI] 8.5-18.7, p<0.0001). Adverse events, primarily gastrointestinal, were more common in the semaglutide group (80%) than placebo (46%). Overall, findings from this study suggest that semaglutide 50 mg leads to a clinically significant decrease in body weight among adults with overweight or obese BMIs and no type 2 diabetes.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: GLP-1 agonistGLP-1 receptor agonistglucoseglycemic controlobesitysemaglutidetype 2 diabetesType 2 Diabetes Mellitus
Previous Post

Prenatal magnesium at 30-34 weeks does not reduce risk of death or cerebral palsy: MAGENTA trial

Next Post

2 Minute Medicine Rewind September 18, 2023

RelatedReports

Type I diabetes not associated with early menopause [OVADIA study]
Endocrinology

Red meat consumption may be associated with an increased risk of type 2 diabetes

December 8, 2023
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

December 7, 2023
#VisualAbstract: Dapagliflozin does not reduce albuminuria in patients with heart failure and type 2 diabetes (DAPPER study)
StudyGraphics

#VisualAbstract: Dapagliflozin does not reduce albuminuria in patients with heart failure and type 2 diabetes (DAPPER study)

December 1, 2023
#VisualAbstract: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
StudyGraphics

#VisualAbstract: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

November 16, 2023
Next Post
Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

2 Minute Medicine Rewind September 18, 2023

#VisualAbstract: Extracorporeal Life Support in Infarct-Related Cardiogenic Shock

#VisualAbstract: Extracorporeal Life Support in Infarct-Related Cardiogenic Shock

Addressing non-obesity related barriers may improve bariatric surgery effectiveness

Patients with anxiety and/or depression may not experience more emergency room visits following bariatric surgery

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Seriesâ„¢ textbook.

Subscription Options

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Specific viruses may be associated with increased risk and worse outcomes of ovarian cancer
  • Low-dose amitriptyline effective and well-tolerated for management of irritable bowel syndrome
  • Patisiran prevents functional decline in patients with cardiac amyloidosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classicsâ„¢
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options